Junevity is pioneering advancements in the field of longevity through its innovative RESET Platform, which leverages large-scale human data and artificial intelligence (AI) to develop novel small interfering RNA (siRNA) therapeutics. This platform specifically targets transcription factors that play a crucial role in cellular health and are often dysregulated in diseases associated with aging. By identifying and restoring the expression of these transcription factors, Junevity aims to address various health issues, including obesity, type 2 diabetes, and frailty, ultimately striving for a future where individuals can enjoy longer and healthier lives.

The foundation of Junevity's approach is rooted in breakthrough research conducted at UCSF, where the company’s founders utilized machine learning and high-throughput screening to uncover pathways that become overactive with age and disease. The RESET Platform not only combines advanced AI and modern laboratory techniques but also focuses on the therapeutic potential of siRNA, an area that has been relatively underexplored in drug discovery. By collaborating with pharmaceutical companies, Junevity is positioned to develop transformative therapeutics that reset cellular health and combat the transcriptional dysregulation that contributes to age-related diseases.

United States

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Junevity

Company Details